New stock news | Weijian Pharmaceutical's Hong Kong IPO prospectus fails to take effect.

Weiji International Holdings Group Limited (referred to as Weiji Pharmaceuticals) submitted its Hong Kong stock prospectus on November 7, 2025, which expired 6 months later on May 7, 2026. Huatai International was its exclusive sponsor when submitting the prospectus. According to the previous prospectus, Weiji Pharmaceuticals is a leading comprehensive pharmaceutical company in China focused on the treatment of kidney and blood diseases, with integrated capabilities in drug development, production, and commercialization. The company is committed to addressing significant clinical needs in the treatment of kidney, blood, and other major diseases by providing innovative and valuable treatment solutions. Weiji Pharmaceuticals has built a diverse and differentiated product portfolio covering a wide range of kidney, blood, respiratory, skin, and other major disease areas. As of the last feasible date, Weiji Pharmaceuticals' product portfolio includes over 20 commercialized drugs and 1 candidate drug, including five drugs acquired as part of the Concord Kirin China acquisition, four drugs exclusively licensed in China, and over 10 third-party drugs sold and/or promoted through the CSO model. The company's two core therapeutic areas in the product portfolio, chronic kidney disease and blood diseases, affect a large number of patients.